Caribou Biosciences (NASDAQ:CRBU) Stock Rating Upgraded by Wall Street Zen

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Saturday.

Separately, HC Wainwright reiterated a "buy" rating and issued a $3.00 price target (down previously from $9.00) on shares of Caribou Biosciences in a research note on Monday, April 28th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $8.50.

Caribou Biosciences Stock Performance

Shares of Caribou Biosciences stock traded up $0.21 during trading hours on Friday, reaching $1.60. 2,566,556 shares of the company were exchanged, compared to its average volume of 1,329,397. The firm has a market cap of $148.80 million, a PE ratio of -0.99 and a beta of 2.48. Caribou Biosciences has a 1 year low of $0.66 and a 1 year high of $3.00. The stock's fifty day moving average is $1.11 and its 200 day moving average is $1.18.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share for the quarter, hitting the consensus estimate of ($0.43). The company had revenue of $2.35 million for the quarter, compared to the consensus estimate of $1.48 million. Caribou Biosciences had a negative return on equity of 55.70% and a negative net margin of 1,490.84%. Research analysts expect that Caribou Biosciences will post -1.64 earnings per share for the current year.

Hedge Funds Weigh In On Caribou Biosciences

Several hedge funds have recently added to or reduced their stakes in CRBU. US Bancorp DE boosted its holdings in shares of Caribou Biosciences by 3,524.2% in the 4th quarter. US Bancorp DE now owns 27,218 shares of the company's stock valued at $43,000 after buying an additional 26,467 shares in the last quarter. Thrivent Financial for Lutherans lifted its position in Caribou Biosciences by 74.4% in the fourth quarter. Thrivent Financial for Lutherans now owns 186,621 shares of the company's stock valued at $297,000 after acquiring an additional 79,636 shares during the last quarter. Intech Investment Management LLC boosted its stake in Caribou Biosciences by 69.4% in the fourth quarter. Intech Investment Management LLC now owns 37,478 shares of the company's stock valued at $60,000 after acquiring an additional 15,352 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of Caribou Biosciences by 9.2% during the fourth quarter. American Century Companies Inc. now owns 159,822 shares of the company's stock worth $254,000 after purchasing an additional 13,421 shares during the last quarter. Finally, Sei Investments Co. purchased a new position in shares of Caribou Biosciences during the fourth quarter worth about $102,000. 77.51% of the stock is currently owned by hedge funds and other institutional investors.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.